Pacific Biosciences of California, Inc. reports results for the quarter ended June 30 - Earnings Summary

Pacific Biosciences of California

05/08/2026 23:40

Pacific Biosciences of California, Inc. PACB.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of seven analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -14 cents to -12 cents per share.
Revenue fell 1.9% to $39.01 million from a year ago; analysts expected $40.07 million. 
Pacific Biosciences of California, Inc.'s reported EPS for the quarter was a loss of 14 cents​.
The company reported a quarterly loss of $44.74 million.
Pacific Biosciences of California, Inc. shares had fallen by 14.3% this quarter and lost 23.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Pacific Biosciences of California, Inc. is $2.63, about 45.1% above its last closing price of $1.44
This summary was machine generated from LSEG data August 5 at 10:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.13
-0.14
Missed
Mar. 31 2026 
-0.13
-0.12
Beat
Dec. 31 2025 
-0.15
-0.12
Beat
Sep. 30 2025 
-0.15
-0.13
Beat